BlossomHill Therapeutics, Inc. Common Stock (BLSM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BlossomHill Therapeutics, Inc. Common Stock (BLSM) has a cash flow conversion efficiency ratio of 0.138x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.94 Million) by net assets ($-152.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BLSM market cap overview for the company's overall valuation and market capitalisation.
BlossomHill Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how BlossomHill Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BlossomHill Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BlossomHill Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See cash flow to debt ratio of BlossomHill Therapeutics, Inc. Common St to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhongbai Holdings Group Co Ltd
SHE:000759
|
-0.009x |
|
Shenandoah Telecommunications Co
NASDAQ:SHEN
|
0.025x |
|
Neurogene Inc
NASDAQ:NGNE
|
-0.110x |
|
PNE AG
XETRA:PNE3
|
-0.170x |
|
Achieve Life Sciences Inc
NASDAQ:ACHV
|
-0.649x |
|
Sumber Global Energy Tbk Pt
JK:SGER
|
0.029x |
|
Stx Engine
KO:077970
|
0.003x |
|
Slate Grocery REIT
TO:SGR-UN
|
0.019x |
Annual Cash Flow Conversion Efficiency for BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025. View BLSM share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-131.73 Million | $-46.92 Million | 0.356x | -17.36% |
| 2024-12-31 | $-72.88 Million | $-31.42 Million | 0.431x | -- |
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients w… Read more